Tong X.-L.,Chinese Academy of Sciences |
Lian F.-M.,Chinese Academy of Sciences |
Zhou Q.,Chinese Academy of Sciences |
Xu L.-P.,Beijing University of Chinese Medicine |
And 13 more authors.
American Journal of Chinese Medicine | Year: 2013
A prospective multicenter clinical trial was conducted to compare the beneficial effects of a Chinese herbal medicine formula Jiangzhuoqinggan (JZQG) and western antihypertension drug irbesartan. JZQG is mainly composed of rhubarb, coptis, cassia, and uncaria. A total of 240 patients with mild to moderate hypertension were enrolled in the trial. Patients were assigned into two groups after screening: JZQG group and the irbesartan group. After four weeks of treatment, we compared the changes in routine blood pressure, 24 h ambulatory blood pressure, and waist circumference. There was a significant reduction in systolic blood pressure and diastolic blood pressure in the JZQG group (both p < 0.01). There were no significant differences between the reduction of systolic and diastolic blood pressures in the two treatment groups. From the 24 h ambulatory blood pressure measurement, the JZQG group showed a greater reduction in both systolic and diastolic blood pressures (in both daytime and nighttime) than the irbesartan group. Furthermore, there was a significant difference in waist circumference in the JZQG group (1.51 cm reduction; P < 0.05) but not the irbesartan group (0.42 cm). Thus, the JZQG formula may have therapeutic value in patients with both hypertension and metabolic syndrome. © 2013 World Scientific Publishing Company.
Lian F.,Chinese Academy of Sciences |
Wu L.,Chinese Academy of Sciences |
Tian J.,Chinese Academy of Sciences |
Jin M.,China Japan Friendship Hospital |
And 10 more authors.
Journal of Ethnopharmacology | Year: 2015
Ethnopharmacological relevance Salvia miltiorrhiza (Danshen in Chinese) is a common traditional Chinese herbal medicine often used to treat many medical conditions. The Compound Danshen Dripping Pill (CDDP) is a danshen-containing Chinese herbal product for the treatment of cardiovascular diseases. However, to date, no controlled clinical studies have been conducted to evaluate the effects of CDDP on diabetic retinopathy (DR). Aim of the study The present large-scale clinical trial was designed to assess the effectiveness and safety of CDDP in treating patients with non-proliferative diabetic retinopathy (NPDR). Materials and methods 223 NPDR patients were enrolled in this controlled trial. Subjects received oral study medications three times daily for 24 weeks. The four groups were placebo, low-dose (270 mg), mid-dose (540 mg) and high dose (810 mg herbal medicine). Primary endpoints were changes in fluorescence fundus angiography (FFA) and fundoscopic examination parameters. Results and discussion At 24 weeks, for the FFA, the percent of "Excellent" and "Effective" in the high-dose and mid-dose CDDP groups was 74% and 77%, respectively, very significantly higher than 28% in the placebo group (P<0.001). For fundoscopic examination, the percent of "Excellent" and "Effective" in the high-dose and mid-dose CDDP groups was 42% and 59%, respectively, very significantly higher than 11% in the placebo group (P<0.001). No adverse events with clinical significance were observed. Conclusions DR is a severe microvascular complication of diabetes and a major cause of adult blindness worldwide. Our clinical trial data demonstrated the therapeutic value and safety of a danshen-containing Chinese herbal medicine in patients with diabetic retinopathy. © 2015 Elsevier Ireland Ltd. All rights reserved.
Gong J.,Tianjin Tasly Pride Pharmaceutical Co. |
Ju A.,Tianjin Tasly Pride Pharmaceutical Co. |
Zhou D.,Tianjin Tasly Pride Pharmaceutical Co. |
Li D.,Tianjin Tasly Pride Pharmaceutical Co. |
And 10 more authors.
Molecules | Year: 2015
Salvianolic acid Y (TSL 1), a new phenolic acid with the same planar structure as salvianolic acid B, was isolated from Salvia officinalis. The structural elucidation and stereochemistry determination were achieved by spectroscopic and chemical methods, including 1D, 2D-NMR ( 1H-1H COSY, HMQC and HMBC) and circular dichroism (CD) experiments. The biosynthesis pathway of salvianolic acid B and salvianolic acid Y (TSL 1) was proposed based on structural analysis. The protection of PC12 cells from injury induced by H2 O2 was assessed in vitro using a cell viability assay. Salvianolic acid Y (TSL 1) protected cells from injury by 54.2%, which was significantly higher than salvianolic acid B (35.2%). © 2015 by the authors licensee MDPI Basel Switzerland.
Zhou Q.,Chinese Academy of Sciences |
Chang B.,Tianjin Medical University |
Chen X.-Y.,Chinese Academy of Sciences |
Zhou S.-P.,Tasly Pharmaceutical Co. |
And 11 more authors.
American Journal of Chinese Medicine | Year: 2014
Obesity is a serious medical problem worldwide. As a holistic therapy, traditional Chinese medicine (TCM) may have a potential in obesity management. In this controlled trial, we evaluated the safety and effectiveness of Xin-Ju-Xiao-Gao-Fang (XJXGF), a TCM herbal formulation, in 140 obese subjects over a 24-week period. The XJXGF formula mainly consists of rhubarb, coptis, semen cassia, and citrus aurantium. Subjects with body mass index (BMI) 28-40 kg/m2 were recruited at 5 centers in China. We assessed the changes in subjects' body weight, its related parameters, and the reduction of insulin resistance (IR) after administration of XJXGF formula or low-dose XJXGF (10% of the XJXGF formula, as control). After 24-week treatment, among participants in the XJXGF formula group and low-dose XJXGF group, the mean ± SE changes in the body weight were -3.58 ± 0.48 and -1.91 ± 0.38 kg, respectively (p < 0.01). The changes in the IR-index of two groups were -2.65 ± 1.04 and -1.58 ± 1.3, respectively (p < 0.05). There were no serious adverse events reported during the 24-week trial. Participants reported 7 minor adverse events, 4 in the XJXGF formula group and 3 in the low-dose XJXGF group (p = 0.578). Future studies are needed to investigate the clinical utility of this TCM formulation in the treatment of obese subjects. © 2014 World Scientific Publishing Company & Institute for Advanced Research in Asian Science and Medicine.
Tong X.L.,Chinese Academy of Sciences |
Wu S.T.,Tianjin University of Traditional Chinese Medicine |
Lian F.M.,Chinese Academy of Sciences |
Zhao M.,Tasly Pharmaceutical Co. |
And 10 more authors.
Diabetes, Obesity and Metabolism | Year: 2013
Aim: TM81 (or Tang-Min-Ling-Wan) is a Chinese medicine. Previous studies suggested that this medicine is effective for treating type 2 diabetes. This controlled trial evaluated the safety and effectiveness of TM81 in the treatment of type 2 diabetic patients. Methods: This study was a large-scale controlled clinical trial to evaluate the safety and effectiveness of TM81 on type 2 diabetes. After a 2-week run-in period, 480 overweight type 2 early-stage diabetic patients [35-65years old, HbA1c ≥ 7.0%, fasting plasma glucose (FPG) 7.0-13.9mM or 2h plasma glucose (PG)>11.1mM, body mass index (BMI)≥24kg/m2] were enrolled. These patients were divided into a TM81 group and placebo group in a 3:1 ratio. The subjects received 6g TM81 or placebo, three times daily for 12weeks. Results: After treatment, the HbA1c decrease was 1.02% in the TM81 group versus 0.47% in the placebo group. The FPG decreased 0.8±0.1 mM in the TM81 group versus an increase of 0.2±0.2mM in the placebo group. The PG decreased 2.7±0.3 mM in the TM81 group versus a decrease of 0.9±0.4 mM in the placebo group (all p<0.05). The TM81 was more effective for patients with higher baseline HbA1c levels. The TM81 group also showed improved β-cell function and increased homeostatic model assessment (HOMA)-β. In addition, body weight, BMI and waist circumference of subjects in the TM81 group were reduced, and the symptoms related to diabetes were improved. There were no significant differences in the types and frequency of adverse reactions between the two groups. Conclusions: The data showed that TM81 is effective in controlling blood glucose level and is safe to use in patients with early-stage type 2 diabetes. © 2012 Blackwell Publishing Ltd.